Cingulate Inc. (CING)

Market Cap	10.77M
Revenue (ttm)	n/a
Net Income (ttm)	-19.10M
Shares Out	2.18M
EPS (ttm)	-24.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	252,941
Open	5.070
Previous Close	5.170
Day's Range	4.850 - 5.230
52-Week Range	1.800 - 187.200
Beta	-0.89
Analysts	Buy
Price Target	96.00 (+1,843.32%)
Earnings Date	Nov 11, 2024

About CING

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-21...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2021
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CING
• Website: https://www.cingulate.com

Analyst Forecast

According to 3 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $96.0, which is an increase of 1,843.32% from the latest price.

Price Target

$96.0

(1,843.32% upside)

Analyst Consensus: Buy